Autolus Therapeutics PLC Sponsored ADR $AUTL Shares Bought by Cetera Investment Advisers

Cetera Investment Advisers lifted its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 47.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 524,872 shares of the company's stock after purchasing an additional 168,650 shares during the quarter. Cetera Investment Advisers owned about 0.20% of Autolus Therapeutics worth $814,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Two Sigma Investments LP grew its stake in shares of Autolus Therapeutics by 23.8% during the 4th quarter. Two Sigma Investments LP now owns 906,767 shares of the company's stock worth $2,131,000 after purchasing an additional 174,485 shares during the period. Renaissance Technologies LLC boosted its position in shares of Autolus Therapeutics by 146.7% in the 4th quarter. Renaissance Technologies LLC now owns 618,942 shares of the company's stock worth $1,455,000 after buying an additional 368,071 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Autolus Therapeutics by 392.0% in the 4th quarter. Legal & General Group Plc now owns 297,736 shares of the company's stock worth $697,000 after buying an additional 237,224 shares in the last quarter. Millennium Management LLC boosted its position in shares of Autolus Therapeutics by 91.6% in the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock worth $3,885,000 after buying an additional 790,437 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Autolus Therapeutics in the 4th quarter worth about $26,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AUTL shares. Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, July 21st. Finally, Wells Fargo & Company decreased their price objective on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Autolus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.12.

Autolus Therapeutics Price Performance

NASDAQ:AUTL traded up $0.03 on Monday, reaching $1.81. The stock had a trading volume of 1,194,975 shares, compared to its average volume of 1,863,472. The company has a market cap of $480.38 million, a price-to-earnings ratio of -2.17 and a beta of 1.90. The firm's fifty day moving average is $2.32 and its two-hundred day moving average is $1.89. Autolus Therapeutics PLC Sponsored ADR has a 12-month low of $1.11 and a 12-month high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to analysts' expectations of $12.92 million. As a group, research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.